igg2c fitc polyclonal Search Results


igg2c fitc  (SouthernBiotech)
95
SouthernBiotech igg2c fitc
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Igg2c Fitc, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg2c fitc/product/SouthernBiotech
Average 95 stars, based on 1 article reviews
igg2c fitc - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti-igg2c-fitc (polyclonal  (Bio-Rad)
90
Bio-Rad anti-igg2c-fitc (polyclonal
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Anti Igg2c Fitc (Polyclonal, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-igg2c-fitc (polyclonal/product/Bio-Rad
Average 90 stars, based on 1 article reviews
anti-igg2c-fitc (polyclonal - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
hrp southernbiotech  (SouthernBiotech)
93
SouthernBiotech hrp southernbiotech
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Hrp Southernbiotech, supplied by SouthernBiotech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/hrp southernbiotech/product/SouthernBiotech
Average 93 stars, based on 1 article reviews
hrp southernbiotech - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
igg2c  (Bio-Rad)
94
Bio-Rad igg2c
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Igg2c, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/igg2c/product/Bio-Rad
Average 94 stars, based on 1 article reviews
igg2c - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
fitc anti igg2c  (Bethyl)
94
Bethyl fitc anti igg2c
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Fitc Anti Igg2c, supplied by Bethyl, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fitc anti igg2c/product/Bethyl
Average 94 stars, based on 1 article reviews
fitc anti igg2c - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
goat anti mouse igg2c antibody fitc conjugated bethyl  (Bethyl)
93
Bethyl goat anti mouse igg2c antibody fitc conjugated bethyl
(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and <t>IgG2c</t> + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.
Goat Anti Mouse Igg2c Antibody Fitc Conjugated Bethyl, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat anti mouse igg2c antibody fitc conjugated bethyl/product/Bethyl
Average 93 stars, based on 1 article reviews
goat anti mouse igg2c antibody fitc conjugated bethyl - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier

Image Search Results


(A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and IgG2c + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.

Journal: bioRxiv

Article Title: Pathogenic IgE-fated B cell memory retains functional plasticity

doi: 10.1101/2023.11.28.567094

Figure Lengend Snippet: (A) Expression level of Ighc genes downstream of Ighg1 from scRNA-seq analysis of B cells isolated from spleens and inguinal LNs of CT-immunized mice and A4RA/IC-treated epicutaneously sensitized mice. Gene expression is plotted for cells within the MBC cluster . (B) VDJ analysis of MBC cluster. Plot depicts the assigned Ighc gene in MBCs with ≥3 nucleotide mutations compared to the germline sequence. (C) Representative contour plots of IgG1 + and IgG2c + populations from inguinal LNs of IC/A4RA-treated epicutaneously sensitized mice four weeks post-boost and antibody treatment. (D) IC/A4RA-treated mice were rested up to 15 weeks after re-exposures. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four and 15 weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (E) Epicutaneously sensitized mice were treated with A4RA, AIFNG, or both at the time of subcutaneous re-exposure. IgG1 + (left) and IgG2c + (right) MBC frequency are plotted at four weeks post-boost. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . (F) OVA-specific serum immunoglobulin profiles of IC/A4RA-treated mice at zero to 15 weeks post-boost. (G) IC/A4RA-treated mice were rested for nine weeks to allow for clearance of OVA-specific IgG2c and clearance of IC/A4RA blocking antibodies. Subsequently, mice received tertiary OVA exposures and serum was collected at week 12. OVA-specific serum immunoglobulin profiles are depicted before and after tertiary exposures. (C-G) Data represents 2 experiments with at least 4 mice per group. Data are presented as mean ± SEM (F, G) or median ± min/max (D, E). * p < 0.05, ** p < 0.01, *** p < 0.001. Seq, sequences; swIg, class-switched; AIFNG, anti-IFN-ψR1; OD, optical density.

Article Snippet: The following anti-mouse fluorochrome-conjugated antibodies were used: B220-AF700 (RA3-6B2), CD138-PE/Dazzle 594 (281– ), CD3-BV711 (17A2), CD3-BV510 (17A2), F4/80-BV711 (BM8), F4/80-BV510 (BM8), CD38-PE/Cy7 (90), GL7-PerCP.Cy5.5 (GL7), GL7-BV421 (GL7; BD, Franklin Lakes, NJ), IgD-Pacific Blue (11-26c.2a), IgD-BV605 (11-26c.2a), IgM-BV786 (II/41; BD), IgM-FITC (II/41), IgG1-BV650 (RMG1-1), IgG2b-PECy7 (RMG2b-1), IgG2c-FITC (polyclonal; SouthernBiotech, Birmingham, AL), IL-4Rα-PE (REA235; Miltenyi Biotec), and CD23-BV421 (B3B4).

Techniques: Expressing, Isolation, Gene Expression, Sequencing, Blocking Assay

(A) Adoptive transfer schematic. (B) WT mice were immunized with OVA + Alum, CT, or CpG. Representative contour plots class-switched OVA + MBCs. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . Numbers indicate the proportion of IgG1 + , IgG2b + , and IgG2c + cells from the parent class-switched MBC population. (C) OVA-enriched B cells were adoptively transferred from WT OVA-Alum donor mice to naïve muMT mice and recipient were boosted with either OVA + CT or OVA + CpG. Summary plots show OVA + IgG1 + and OVA + IgG2c + B cell frequency in recipient mice one week post-transfer and boost. (D) OVA-specific serum immunoglobulin profiles in recipient mice one week post-transfer and boost. Data represents 2 experiments, each with 2-4 mice per group. Data are presented as median ± min/max (B) or mean ± SEM (D). * p < 0.05.

Journal: bioRxiv

Article Title: Pathogenic IgE-fated B cell memory retains functional plasticity

doi: 10.1101/2023.11.28.567094

Figure Lengend Snippet: (A) Adoptive transfer schematic. (B) WT mice were immunized with OVA + Alum, CT, or CpG. Representative contour plots class-switched OVA + MBCs. Pre-gated as OVA + B cells > CD38 + GL7 - > IgM - IgD - . Numbers indicate the proportion of IgG1 + , IgG2b + , and IgG2c + cells from the parent class-switched MBC population. (C) OVA-enriched B cells were adoptively transferred from WT OVA-Alum donor mice to naïve muMT mice and recipient were boosted with either OVA + CT or OVA + CpG. Summary plots show OVA + IgG1 + and OVA + IgG2c + B cell frequency in recipient mice one week post-transfer and boost. (D) OVA-specific serum immunoglobulin profiles in recipient mice one week post-transfer and boost. Data represents 2 experiments, each with 2-4 mice per group. Data are presented as median ± min/max (B) or mean ± SEM (D). * p < 0.05.

Article Snippet: The following anti-mouse fluorochrome-conjugated antibodies were used: B220-AF700 (RA3-6B2), CD138-PE/Dazzle 594 (281– ), CD3-BV711 (17A2), CD3-BV510 (17A2), F4/80-BV711 (BM8), F4/80-BV510 (BM8), CD38-PE/Cy7 (90), GL7-PerCP.Cy5.5 (GL7), GL7-BV421 (GL7; BD, Franklin Lakes, NJ), IgD-Pacific Blue (11-26c.2a), IgD-BV605 (11-26c.2a), IgM-BV786 (II/41; BD), IgM-FITC (II/41), IgG1-BV650 (RMG1-1), IgG2b-PECy7 (RMG2b-1), IgG2c-FITC (polyclonal; SouthernBiotech, Birmingham, AL), IL-4Rα-PE (REA235; Miltenyi Biotec), and CD23-BV421 (B3B4).

Techniques: Adoptive Transfer Assay